Arcutis Biotherapeutics, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:ARQT
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 219 out of 922
Universe
Global Universe 8290 out of 16175
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Arcutis Biotherapeutics, Inc. |
25.2
Medium
|
219 out of 922 |
Mega Lifesciences Public Co. Ltd. |
28.1
Medium
|
428 out of 922 |
Great Tree Pharmacy Co., Ltd. |
35.1
High
|
768 out of 922 |
Chong Kun Dang Pharmaceutical Corp. |
35.1
High
|
770 out of 922 |
Cassava Sciences, Inc. |
35.8
High
|
795 out of 922 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Arcutis Biotherapeutics, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Arcutis Biotherapeutics, Inc.'s Management of ESG Material Risk is Strong